IL112112A - Peptides with growth hormone releasing properties and pharmaceutical compositions containing them - Google Patents

Peptides with growth hormone releasing properties and pharmaceutical compositions containing them

Info

Publication number
IL112112A
IL112112A IL11211294A IL11211294A IL112112A IL 112112 A IL112112 A IL 112112A IL 11211294 A IL11211294 A IL 11211294A IL 11211294 A IL11211294 A IL 11211294A IL 112112 A IL112112 A IL 112112A
Authority
IL
Israel
Prior art keywords
growth hormone
peptides
pharmaceutical compositions
compositions containing
hormone releasing
Prior art date
Application number
IL11211294A
Other languages
English (en)
Other versions
IL112112A0 (en
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143993A external-priority patent/DK143993D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL112112A0 publication Critical patent/IL112112A0/xx
Publication of IL112112A publication Critical patent/IL112112A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL11211294A 1993-12-23 1994-12-22 Peptides with growth hormone releasing properties and pharmaceutical compositions containing them IL112112A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK143993A DK143993D0 (fr) 1993-12-23 1993-12-23
DK12194 1994-01-28
DK119194 1994-10-14

Publications (2)

Publication Number Publication Date
IL112112A0 IL112112A0 (en) 1995-03-15
IL112112A true IL112112A (en) 2000-06-29

Family

ID=27220421

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11211294A IL112112A (en) 1993-12-23 1994-12-22 Peptides with growth hormone releasing properties and pharmaceutical compositions containing them

Country Status (27)

Country Link
US (1) US5767085A (fr)
EP (1) EP0736039B1 (fr)
JP (1) JP3181918B2 (fr)
KR (1) KR100354897B1 (fr)
CN (1) CN1052731C (fr)
AT (1) ATE197158T1 (fr)
AU (1) AU689181B2 (fr)
BR (1) BR9408377A (fr)
CA (1) CA2179597A1 (fr)
CZ (1) CZ293113B6 (fr)
DE (1) DE69426206T2 (fr)
DK (1) DK0736039T3 (fr)
ES (1) ES2153469T3 (fr)
FI (1) FI962584A (fr)
GR (1) GR3035150T3 (fr)
HU (1) HU224345B1 (fr)
IL (1) IL112112A (fr)
MX (1) MX9500072A (fr)
NO (1) NO315561B1 (fr)
NZ (1) NZ277486A (fr)
PL (1) PL181280B1 (fr)
PT (1) PT736039E (fr)
RO (1) RO115635B1 (fr)
SG (1) SG55069A1 (fr)
SK (1) SK281963B6 (fr)
UA (1) UA42747C2 (fr)
WO (1) WO1995017423A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094869B2 (en) 1994-11-16 2006-08-22 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176140A1 (fr) * 1993-11-24 1995-06-01 Meng Hsin Chen Composes contenant un groupe indolyle et leur utilisation pour favoriser la liberation d'hormones(s) de croissance
CN1052730C (zh) * 1993-12-23 2000-05-24 诺沃挪第克公司 具有生长激素释放特性的化合物
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO1996022997A1 (fr) 1995-01-27 1996-08-01 Novo Nordisk A/S Composes ayant des proprietes de liberation de l'hormone de croissance
EP0833845A1 (fr) * 1995-06-22 1998-04-08 Novo Nordisk A/S Composes presentant des proprietes de liberation de l'hormone de croissance
WO1997022004A1 (fr) 1995-12-13 1997-06-19 Merck & Co., Inc. Dosage des recepteurs secretagogues d'hormones de croissance
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
DE69637855D1 (de) * 1995-12-22 2009-04-16 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
BR9708854A (pt) * 1996-04-24 1999-08-03 Novo Nordisk As Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e para aumentar a taxa e grau de crescimento de animais e uso de um composto
US5919777A (en) * 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP1184370B1 (fr) 1996-07-22 2005-09-14 Novo Nordisk A/S Composés ayant des propriétés de libération de l'hormone de croissance
AU3938797A (en) * 1996-08-29 1998-03-19 Novo Nordisk A/S Transdermal delivery of peptides
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1999036431A1 (fr) 1998-01-16 1999-07-22 Novo Nordisk A/S Composes avec proprietes de liberation de l'hormone de croissance
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
WO2000002919A1 (fr) 1998-07-13 2000-01-20 Merck & Co., Inc. Recepteurs et acides nucleiques en rapport avec un secretagogue d'hormone de croissance
WO2000009538A2 (fr) 1998-08-10 2000-02-24 Merck & Co., Inc. Recepteur de secretagogue d'hormone de croissance canine
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
KR100699404B1 (ko) * 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
CA2375148A1 (fr) * 1999-06-04 2000-12-14 Novo Nordisk A/S Compositions destinees au traitement de l'etat catabolique dans les maladies critiques de longue duree
ATE389416T1 (de) 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
EP1159964B1 (fr) 2000-05-31 2009-10-28 Pfizer Products Inc. Utilisation de secrétagogues d'hormones de croissance pour stimuler la motilité gastrointestinale
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
EA008572B1 (ru) * 2003-05-19 2007-06-29 Уорнер-Ламберт Компани Ллс Твёрдая желатиновая капсула, содержащая оксид титана с контролируемым размером частиц, и способ её получения
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
WO2005027913A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un secretagogue de l'hormone de croissance
WO2005097261A1 (fr) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Procede de reduction de la proteine c-reactive a l'aide de secretagogues de l'hormone de croissance
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
WO2007127457A2 (fr) * 2006-04-28 2007-11-08 The Administrators Of The Tulane Educational Fund Antagonistes de récepteur de sécrétagogue d'hormone de croissance/de peptide libérant une hormone de croissance/de ghréline et utilisations de ceux-ci
EP2118080B1 (fr) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Modulateurs macrocycliques du récepteur de la ghréline et leurs procédés d'utilisation
EA200970764A1 (ru) * 2007-02-13 2010-04-30 ХЕЛСИНН ТЕРАПЬЮТИКС (Ю. Эс.), ИНК. Способ лечения расстройств, вызванных пролиферацией клеток, с применением стимуляторов секреции гормона роста
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
WO2008134828A2 (fr) 2007-05-04 2008-11-13 Katholieke Universiteit Leuven Protection contre la dégénérescence tissulaire
EP2225226B1 (fr) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Composés et leur utilisation dans un procédé pour le traitement du cancer
WO2010006438A1 (fr) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Composés inhibiteurs et procédés de traitement du cancer
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
JP2012529510A (ja) * 2009-06-12 2012-11-22 ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド イパモレリンジアセタートの注射用および輸液用の溶液
WO2011120153A1 (fr) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Composés et méthodes pour le traitement du vih
WO2013190520A2 (fr) 2012-06-22 2013-12-27 The General Hospital Corporation Agents de libération de gh dans le traitement d'une sténose vasculaire et d'états associés
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2017075535A1 (fr) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Méthodes de traitement de troubles neurodégénératifs
US12012467B2 (en) 2017-03-28 2024-06-18 Regents Of The University Of Michigan Small molecule DCN1 inhibitors and therapeutic methods using the same
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
BR8208035A (pt) * 1981-12-28 1983-11-22 Beckman Instruments Inc Peptideos sinteticos tendo atividade liberadora de hormonio do crescimento da pituitaria
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
EP0663834A4 (fr) * 1992-09-25 1996-01-24 Smithkline Beecham Corp Peptides liberant l'hormone de croissance.
CA2176140A1 (fr) * 1993-11-24 1995-06-01 Meng Hsin Chen Composes contenant un groupe indolyle et leur utilisation pour favoriser la liberation d'hormones(s) de croissance

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094869B2 (en) 1994-11-16 2006-08-22 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues

Also Published As

Publication number Publication date
EP0736039B1 (fr) 2000-10-25
PL181280B1 (pl) 2001-07-31
AU1272495A (en) 1995-07-10
FI962584A0 (fi) 1996-06-20
GR3035150T3 (en) 2001-04-30
PL315113A1 (en) 1996-10-14
SK281963B6 (sk) 2001-09-11
BR9408377A (pt) 1997-08-19
ES2153469T3 (es) 2001-03-01
RO115635B1 (ro) 2000-04-28
MX9500072A (es) 1997-05-31
DE69426206T2 (de) 2001-05-17
DK0736039T3 (da) 2001-02-12
JPH09507217A (ja) 1997-07-22
DE69426206D1 (de) 2000-11-30
EP0736039A1 (fr) 1996-10-09
ATE197158T1 (de) 2000-11-15
CA2179597A1 (fr) 1995-06-29
CZ293113B6 (cs) 2004-02-18
NO962665L (no) 1996-08-23
UA42747C2 (uk) 2001-11-15
CZ183496A3 (en) 1997-02-12
NO315561B1 (no) 2003-09-22
CN1052731C (zh) 2000-05-24
SG55069A1 (en) 1998-12-21
HUT73497A (en) 1996-08-28
SK82096A3 (en) 1997-01-08
PT736039E (pt) 2001-04-30
AU689181B2 (en) 1998-03-26
JP3181918B2 (ja) 2001-07-03
KR100354897B1 (ko) 2003-01-06
NZ277486A (en) 1997-03-24
WO1995017423A1 (fr) 1995-06-29
FI962584A (fi) 1996-06-20
HU9501947D0 (en) 1995-11-28
NO962665D0 (no) 1996-06-21
IL112112A0 (en) 1995-03-15
US5767085A (en) 1998-06-16
CN1138335A (zh) 1996-12-18
HU224345B1 (hu) 2005-08-29

Similar Documents

Publication Publication Date Title
IL112112A (en) Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
GR3029791T3 (en) Improved immunogenic compositions against human gastrin 17
TW279166B (fr)
PL315114A1 (en) Compounds exhibiting properties of releasing growth hormones
GR3022510T3 (en) Lyospheres comprising gonadotropin
MY113488A (en) Compounds with growth hormone releasing properties
GR3024157T3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy.
SE9101838D0 (sv) Novel peptides and their use
GR3031687T3 (en) Hgh containing pharmaceutical compositions
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
GB9015774D0 (en) Novel treatment
MX9710377A (es) Compuestos con propiedades de liberacion de la hormona de crecimiento.
JO1711B1 (en) Therapeutic agents
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees